两剂HBsAg/CpG 1018乙肝疫苗在60-70岁2型糖尿病人群中的免疫原性与安全性
该研究为一项3期临床试验的事后分析,纳入60-70岁2型糖尿病患者,比较2剂HBsAg/CpG 1018疫苗(HEPLISAV-B)与3剂HBsAg/alum疫苗(Engerix-B)的免疫原性和安全性。结果显示第28周HBsAg/CpG 1018组血清保护率(SPR)显著高于HBsAg/alum组(85.8% vs 58.5%,差异27.3%,95%CI 18.0-36.8),且不受性别、BMI或吸烟状态影响,两组不良事件和死亡相当。
要点
- 60-70岁2型糖尿病患者中,2剂HBsAg/CpG 1018疫苗第28周SPR达85.8%,显著高于3剂HBsAg/alum的58.5%。
- HBsAg/CpG 1018在各亚组(性别、BMI、吸烟状态)中SPR均一致高于HBsAg/alum。
- 两组不良事件和死亡可比,安全性特征相似。
核心结论
- 在60-70岁2型糖尿病患者中,2剂HBsAg/CpG 1018疫苗比3剂HBsAg/alum疫苗提供更高的乙肝血清保护水平,且安全性相似。
研究设计与样本
- 3期临床试验的事后分析,60-70岁2型糖尿病患者接受2剂HBsAg/CpG 1018(HEPLISAV-B,n=327,0和4周,24周安慰剂)或3剂HBsAg/alum(Engerix-B,n=153,0、4、24周)。
- 按性别、体质指数和吸烟状态进行亚组分析,评估第28周血清保护率(SPR,定义为抗HBs血清浓度≥10 mIU/mL)和安全性。
主要发现
- 符合方案分析中,第28周HBsAg/CpG 1018组SPR为85.8%(235/274),HBsAg/alum组为58.5%(76/130),总体差异27.3%(95%CI 18.0-36.8)。
- 无论性别、体质指数或吸烟状态,HBsAg/CpG 1018组SPR均一致 markedly 高于HBsAg/alum组。
- 两组不良事件和死亡相当。
关键数值与推荐
- 血清保护率(SPR)定义为抗乙肝表面抗原抗体血清浓度≥10 mIU/mL。
- 第28周SPR:HBsAg/CpG 1018组85.8%(235/274),HBsAg/alum组58.5%(76/130),差异27.3%(95%CI 18.0-36.8)。
临床怎么用
- 对于60-70岁2型糖尿病患者,可考虑选用2剂HBsAg/CpG 1018疫苗以在较短时间内获得更高的血清保护率。
- 该人群接种乙肝疫苗时,HBsAg/CpG 1018方案(0、4周)可能比3剂HBsAg/alum方案(0、4、24周)更早达到高保护水平。
局限性
- 本研究为3期临床试验的事后分析,结果需进一步在前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus (HBV) remains a major public health issue, although it is a vaccine-preventable disease. Adults with diabetes are at greater risk of contracting HBV than the general population. Commonly used 3-dose HBV vaccines have reduced immunogenicity in older individuals and in those with diabetes mellitus. METHODS: In this post hoc analysis of a phase 3 clinical trial, participants with type 2 diabetes mellitus aged 60-70 years received either 2-dose HBsAg/CpG 1018 (HEPLISAV-B®, n = 327) at 0 and 4 weeks and placebo at 24 weeks or 3-dose HBsAg/alum (Engerix-B®, n = 153) at 0, 4, and 24 weeks. Immunogenicity, including seroprotection rate (SPR) at week 28, and safety were assessed by subgroup (sex, body mass index, and smoking status). SPR was defined as antibody against hepatitis B surface antigen serum concentration ≥10 mIU/mL. RESULTS: The SPR at week 28 was significantly higher with HBsAg/CpG 1018 (85.8% [235/274]) than with HBsAg/alum (58.5% [76/130]) in the per-protocol analysis, for an overall difference of 27.3% (95% CI, 18.0-36.8). SPRs with HBsAg/CpG 1018 were consistently markedly higher compared with HBsAg/alum, regardless of sex, body mass index, or smoking status. Adverse events and deaths were comparable between groups. CONCLUSIONS: Two-dose HBsAg/CpG 1018 provides a higher level of seroprotection against HBV than does a 3-dose vaccine (HBsAg/alum) with a similar safety profile in patients aged 60-70 years with type 2 diabetes mellitus. Study identifier: NCT02117934.
引用
- Hyer RN, Janssen RS. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years. Vaccine. 2019. PMID: 31431412. doi:10.1016/j.vaccine.2019.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。